Table 1 Functional analysis of the antibody microarray data obtained from PSC secretome upon TNF-α treatment.

From: Impact of the secretome of activated pancreatic stellate cells on growth and differentiation of pancreatic tumour cells

Functional Annotation

p-Value

Predicted Activation State

z-Score

Molecule Number

Typical Molecules

Invasion of cells

1.21E-23

Increased

2.952

33

CCL11, CSF2, CTGF, FGF2, FN1, IFNG, IGF1, IGF2, IL1B, IL6, TIMP1, TIMP2, TNF, VEGFA, VEGFB, VEGFC, VTN

Stimulation of connective tissue cells

3.14E-19

Increased

2.951

12

CSF2, FGF2, IFNG, IGF1, IL10, IL1B, IL4, IL6, TNF, VEGFA

Generation of reactive oxygen species

1.22E-13

Increased

2.884

15

ALB, CSF2, IFNG, IGF1, IL10, IL1B, IL6, MMP14, SERPINB5, TNF

Migration of cells

1.54E-39

Increased

2.876

58

CCL11, CCL4, CSF2, CTGF, FGF1, FGF2, FN1, IGF1, IL4, IL6, MMP10, MMP11, MMP12, MMP14, TGFBI, THBS2, TIMP1, TIMP2, TNF, VEGFA, VEGFB, VEGFC, VTN

Proliferation of fibroblasts

8.27E-14

Increased

2.747

17

CTGF, DCN, FGF1, FGF2, FN1, IGF1, IGF2, IGFBP3, IL1B, IL4, IL6, TNF,

Growth of tumour

3.50E-31

Increased

2.745

38

CCL11, CSF2, CTGF, FGF1, FGF2, FN1

Proliferation of lymphoma cell lines

1.08E-13

Increased

2.739

13

CCL11, IFNG, IGF1, IGF2, IGFBP1, IGFBP3, IL10, IL15, IL2, IL4, IL6, TF, TNF

Activation of fibroblasts

6.06E-14

Increased

2.563

8

ENO1, IFNG, IGF1, IGFBP3, IL6, VEGFB

Invasion of tumour cell lines

3.90E-18

Increased

2.515

25

CCL11, FGF2, FN1, MMP14, SERPINB5, TIMP1, TIMP2, TNF, VEGFA, VEGFB

Growth of malignant tumour

6.38E-24

Increased

2.412

27

FGF1, FGF2, GRN, IL10, IL12A, IL15, IL1AIL6, KLK3, TNF,

Cell movement of tumour cell lines

1.63E-26

Increased

2.370

35

AREG, CCL11, CCL4, CSF2, CTGF, CXCL10, CXCL8, CXCL9, DCN, FGF1, FGF2,

Migration of tumour cell lines

4.10E-27

Increased

2.364

33

AREG, CCL11, CSF2, CTGF, CXCL10, CXCL8, MMP14, SERPINE1, TGFBI, THBS2, TIMP1, TIMP2, TNF, VEGFA

Proliferation of tumour cell lines

1.58E-24

Increased

2.339

42

IL10, IL12A, IL1B, IL1RN, IL2, IL32, INS

Mitogenesis

1.18E-22

Increased

2.315

19

FGF1, FGF2, GRP, IGF1, IGF2, IGFBP2

Proliferation of antigen presenting cells

1.11E-17

Increased

2.225

13

ENO1, EWSR1, FGF1, FGF2, FLNA, FN1, CSF2, DCN, IFNA1/IFNA13, IFNG, IGF1, IL10

Formation of cells

8.35E-15

Increased

2.219

27

ADCYAP1, ALB, AREG, BGN, CCL11, CCL4, CSF2, CTGF, CXCL10

Proliferation of cells

3.78E-24

Increased

2.150

59

FGF2, FN1, FRZB, GRN, GRP, GSN, IFNA1, IFNA13, IFNG, IGF1, IGF2, IGFBP1, IGFBP2, IGFBP3, IL10, IL12A, IL15, IL1A, IL1B, IL1RN, IL2, IL32, IL4

Activation of cells

8.99E-30

Increased

2.142

41

TF, TG, TIMP1, TNF, TNFSF14, VEGFA, VTN

Proliferation of tumour cells

2.73E-34

Increased

2.130

35

IGFBP3, IL10, IL12A, IL15, IL1A, IL1B, IL1RN, IL2, IL32, IL4, IL6, KLK3

Proliferation of immune cells

2.18E-20

Increased

2.042

30

ALB, CCL11, CCL4, CSF2, CTGF, CXCL10

Proliferation of leukocyte cell lines

8.60E-20

Increased

2.032

18

CSF2, FGF1, FGF2, FN1, IFNG, IGF1

Proliferation of cancer cells

5.56E-22

Increased

2.020

24

AREG, CSF2, CXCL8, DCN, FGF1, FGF2, GRN

Apoptosis of cancer cells

−1.27E-14

Decreased

−2.578

15

ALB, CSF2, FGF2, IFNG, IGF1, IGFBP3, IL10, IL15, IL4, IL6, MMP11, TF, TNF, VEGFA, VEGFC

Apoptosis of tumour cells

−8.67E-21

Decreased

−2.882

21

FGF2, IFNG, IGF1, IGFBP3, IL10, IL15, IL2, IL4, IL6, KLK3, MMP11, TF, TNF, VEGFA, VEGFC

Necrosis of tumour

−1.42E-24

Decreased

−3.598

26

IL1B, IL2, IL4, IL6, KLK3, MMP11, SERPINB5, SERPINE1, TF, THBS2, TIMP1, TIMP2, TNF, VEGFA, VEGFC

Cell death of tumour cells

−1.92E-23

Decreased

−3.598

25

CSF2, CXCL8, FGF2, IFNG, IGF1, IGFBP3, IL10, IL15, IL1A, IL1B, IL2, IL4, IL6, KLK3, MMP11, SERPINB5, SERPINE1, TF, THBS2, TIMP1, TIMP2, TNF, VEGFA, VEGFC

Back to article page